Literature DB >> 28170385

Exhausting alloreactivity of donor-derived CAR T cells.

Maksim Mamonkin1, Helen E Heslop1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28170385     DOI: 10.1038/nm.4276

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Authors:  Arnab Ghosh; Melody Smith; Scott E James; Marco L Davila; Enrico Velardi; Kimon V Argyropoulos; Gertrude Gunset; Fabiana Perna; Fabiana M Kreines; Emily R Levy; Sophie Lieberman; Hillary V Jay; Andrea Z Tuckett; Johannes L Zakrzewski; Lisa Tan; Lauren F Young; Kate Takvorian; Jarrod A Dudakov; Robert R Jenq; Alan M Hanash; Ana Carolina F Motta; George F Murphy; Chen Liu; Andrea Schietinger; Michel Sadelain; Marcel R M van den Brink
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

2.  Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Authors:  Partow Kebriaei; Harjeet Singh; M Helen Huls; Matthew J Figliola; Roland Bassett; Simon Olivares; Bipulendu Jena; Margaret J Dawson; Pappanaicken R Kumaresan; Shihuang Su; Sourindra Maiti; Jianliang Dai; Branden Moriarity; Marie-Andrée Forget; Vladimir Senyukov; Aaron Orozco; Tingting Liu; Jessica McCarty; Rineka N Jackson; Judy S Moyes; Gabriela Rondon; Muzaffar Qazilbash; Stefan Ciurea; Amin Alousi; Yago Nieto; Katy Rezvani; David Marin; Uday Popat; Chitra Hosing; Elizabeth J Shpall; Hagop Kantarjian; Michael Keating; William Wierda; Kim Anh Do; David A Largaespada; Dean A Lee; Perry B Hackett; Richard E Champlin; Laurence J N Cooper
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

3.  Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.

Authors:  Seitaro Terakura; Tori N Yamamoto; Rebecca A Gardner; Cameron J Turtle; Michael C Jensen; Stanley R Riddell
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

4.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Authors:  James N Kochenderfer; Mark E Dudley; Robert O Carpenter; Sadik H Kassim; Jeremy J Rose; William G Telford; Frances T Hakim; David C Halverson; Daniel H Fowler; Nancy M Hardy; Anthony R Mato; Dennis D Hickstein; Juan C Gea-Banacloche; Steven Z Pavletic; Claude Sportes; Irina Maric; Steven A Feldman; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R Bishop; Ronald E Gress; Steven A Rosenberg
Journal:  Blood       Date:  2013-09-20       Impact factor: 22.113

5.  Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Authors:  Matthew J Frigault; Jihyun Lee; Maria Ciocca Basil; Carmine Carpenito; Shinichiro Motohashi; John Scholler; Omkar U Kawalekar; Sonia Guedan; Shannon E McGettigan; Avery D Posey; Sonny Ang; Laurence J N Cooper; Jesse M Platt; F Brad Johnson; Chrystal M Paulos; Yangbing Zhao; Michael Kalos; Michael C Milone; Carl H June
Journal:  Cancer Immunol Res       Date:  2015-01-19       Impact factor: 11.151

6.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Authors:  Jennifer N Brudno; Robert P T Somerville; Victoria Shi; Jeremy J Rose; David C Halverson; Daniel H Fowler; Juan C Gea-Banacloche; Steven Z Pavletic; Dennis D Hickstein; Tangying L Lu; Steven A Feldman; Alexander T Iwamoto; Roger Kurlander; Irina Maric; Andre Goy; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Frances T Hakim; Steven A Rosenberg; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

7.  Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

Authors:  Elad Jacoby; Yinmeng Yang; Haiying Qin; Christopher D Chien; James N Kochenderfer; Terry J Fry
Journal:  Blood       Date:  2015-12-11       Impact factor: 22.113

8.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

9.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

Authors:  Conrad Russell Y Cruz; Kenneth P Micklethwaite; Barbara Savoldo; Carlos A Ramos; Sharon Lam; Stephanie Ku; Oumar Diouf; Enli Liu; A John Barrett; Sawa Ito; Elizabeth J Shpall; Robert A Krance; Rammurti T Kamble; George Carrum; Chitra M Hosing; Adrian P Gee; Zhuyong Mei; Bambi J Grilley; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Catherine M Bollard; Gianpietro Dotti
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

  9 in total
  2 in total

Review 1.  CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.

Authors:  Sasan Ghaffari; Nastaran Khalili; Nima Rezaei
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

Review 2.  Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.

Authors:  Jie Liu; Guangyu Zhou; Li Zhang; Qi Zhao
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.